

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Advances in the management of osteosarcoma | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2767/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2767" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Advances in the management of osteosarcoma" />
    
            <meta name="og:title" content="F1000Research Article: Advances in the management of osteosarcoma.">
            <meta name="og:description" content="Read the latest article version by Stefan S. Bielack, Stefanie Hecker-Nolting, Claudia Blattmann, Leo Kager, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10194">
            <meta name="article-id" content="9465">
            <meta name="dc.title" content="Advances in the management of osteosarcoma">
            <meta name="dc.description" content="Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases. High-grade osteosarcomas are usually treated by preoperative and postoperative chemotherapy and surgery, with a very limited number of active agents available. Rarer lower-grade variants such as parosteal and periosteal osteosarcoma or low-grade central osteosarcoma are treated by surgery only. Imaging to search for possible metastases focuses on the lung. Computed tomography is the most sensitive method but cannot reliably distinguish small metastases from benign lesions. Advances of local imaging and surgical reconstruction now allow the use of limb-salvage in an ever-increasing proportion of patients. While still troubled by complications, non-invasive endoprosthesis-lengthening mechanisms have led to an increased uptake of limb-salvage, even for young, skeletally immature patients. Radiotherapy is employed when osteosarcomas cannot be removed with clear margins, but very high doses are required, and both proton and carbon-ion radiotherapy are under investigation. Unfortunately, the past 30 years have witnessed few, if any, survival improvements. Novel agents have not led to universally accepted changes of treatment standards. In patients with operable high-grade osteosarcomas, the extent of histological response to preoperative chemotherapy is a significant predictive factor for both local and systemic control. Attempts to improve prognosis by adapting postoperative treatment to response, recently tested in a randomized, prospective setting by the European and American Osteosarcoma Study Group, have not been proven to be beneficial. Many agree that only increased knowledge about osteosarcoma biology will lead to novel, effective treatment approaches and will be able to move the field forward.">
            <meta name="dc.subject" content="osteosarcoma, imaging, , surgery, chemotherapy, radiotherapy, ">
            <meta name="dc.creator" content="Bielack, Stefan S.">
            <meta name="dc.creator" content="Hecker-Nolting, Stefanie">
            <meta name="dc.creator" content="Blattmann, Claudia">
            <meta name="dc.creator" content="Kager, Leo">
            <meta name="dc.date" content="2016/11/25">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9465.1">
            <meta name="dc.source" content="F1000Research 2016 5:2767">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="osteosarcoma ">
            <meta name="prism.keyword" content=" imaging ">
            <meta name="prism.keyword" content=" ">
            <meta name="prism.keyword" content="surgery ">
            <meta name="prism.keyword" content=" chemotherapy ">
            <meta name="prism.keyword" content=" radiotherapy ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/11/25">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2767">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9465.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2767">
            <meta name="citation_title" content="Advances in the management of osteosarcoma">
            <meta name="citation_abstract" content="Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases. High-grade osteosarcomas are usually treated by preoperative and postoperative chemotherapy and surgery, with a very limited number of active agents available. Rarer lower-grade variants such as parosteal and periosteal osteosarcoma or low-grade central osteosarcoma are treated by surgery only. Imaging to search for possible metastases focuses on the lung. Computed tomography is the most sensitive method but cannot reliably distinguish small metastases from benign lesions. Advances of local imaging and surgical reconstruction now allow the use of limb-salvage in an ever-increasing proportion of patients. While still troubled by complications, non-invasive endoprosthesis-lengthening mechanisms have led to an increased uptake of limb-salvage, even for young, skeletally immature patients. Radiotherapy is employed when osteosarcomas cannot be removed with clear margins, but very high doses are required, and both proton and carbon-ion radiotherapy are under investigation. Unfortunately, the past 30 years have witnessed few, if any, survival improvements. Novel agents have not led to universally accepted changes of treatment standards. In patients with operable high-grade osteosarcomas, the extent of histological response to preoperative chemotherapy is a significant predictive factor for both local and systemic control. Attempts to improve prognosis by adapting postoperative treatment to response, recently tested in a randomized, prospective setting by the European and American Osteosarcoma Study Group, have not been proven to be beneficial. Many agree that only increased knowledge about osteosarcoma biology will lead to novel, effective treatment approaches and will be able to move the field forward.">
            <meta name="citation_description" content="Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases. High-grade osteosarcomas are usually treated by preoperative and postoperative chemotherapy and surgery, with a very limited number of active agents available. Rarer lower-grade variants such as parosteal and periosteal osteosarcoma or low-grade central osteosarcoma are treated by surgery only. Imaging to search for possible metastases focuses on the lung. Computed tomography is the most sensitive method but cannot reliably distinguish small metastases from benign lesions. Advances of local imaging and surgical reconstruction now allow the use of limb-salvage in an ever-increasing proportion of patients. While still troubled by complications, non-invasive endoprosthesis-lengthening mechanisms have led to an increased uptake of limb-salvage, even for young, skeletally immature patients. Radiotherapy is employed when osteosarcomas cannot be removed with clear margins, but very high doses are required, and both proton and carbon-ion radiotherapy are under investigation. Unfortunately, the past 30 years have witnessed few, if any, survival improvements. Novel agents have not led to universally accepted changes of treatment standards. In patients with operable high-grade osteosarcomas, the extent of histological response to preoperative chemotherapy is a significant predictive factor for both local and systemic control. Attempts to improve prognosis by adapting postoperative treatment to response, recently tested in a randomized, prospective setting by the European and American Osteosarcoma Study Group, have not been proven to be beneficial. Many agree that only increased knowledge about osteosarcoma biology will lead to novel, effective treatment approaches and will be able to move the field forward.">
            <meta name="citation_keywords" content="osteosarcoma, imaging, , surgery, chemotherapy, radiotherapy, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Stefan S. Bielack">
            <meta name="citation_author_institution" content="Klinikum Stuttgart - Olgahospital, Zentrum f&uuml;r Kinder-, Jugend- und Frauenmedizin; P&auml;diatrie 5 (Onkologie, H&auml;matologie, Immunologie), Kriegsbergstrasse 62, Stuttgart Cancer Center, Germany">
            <meta name="citation_author" content="Stefanie Hecker-Nolting">
            <meta name="citation_author_institution" content="Klinikum Stuttgart - Olgahospital, Zentrum f&uuml;r Kinder-, Jugend- und Frauenmedizin; P&auml;diatrie 5 (Onkologie, H&auml;matologie, Immunologie), Kriegsbergstrasse 62, Stuttgart Cancer Center, Germany">
            <meta name="citation_author" content="Claudia Blattmann">
            <meta name="citation_author_institution" content="Klinikum Stuttgart - Olgahospital, Zentrum f&uuml;r Kinder-, Jugend- und Frauenmedizin; P&auml;diatrie 5 (Onkologie, H&auml;matologie, Immunologie), Kriegsbergstrasse 62, Stuttgart Cancer Center, Germany">
            <meta name="citation_author" content="Leo Kager">
            <meta name="citation_author_institution" content="St. Anna Children's Hospital, Department of Paediatrics, Medical University Vienna and Children's Cancer Research Institute CCRI, Vienna, Austria">
            <meta name="citation_publication_date" content="2016/11/25">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2767">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9465.1">
            <meta name="citation_firstpage" content="2767">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2767/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2767.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10194 /> <input type=hidden id=articleId name=articleId value=9465 /> <input type=hidden id=xmlUrl value="/articles/5-2767/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2767-v1.xml"> <input type=hidden id=article_uuid value=dcd86bf4-2e40-4f2f-b441-1443c46f24c0 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Advances in the management of osteosarcoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9465.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9465.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2767"
  },
  "headline": "Advances in the management of osteosarcoma",
  "datePublished": "2016-11-25T15:48:56",
  "dateModified": "2016-11-25T15:48:56",
  "author": [
    {
      "@type": "Person",
      "name": "Stefan S. Bielack"
    },    {
      "@type": "Person",
      "name": "Stefanie Hecker-Nolting"
    },    {
      "@type": "Person",
      "name": "Claudia Blattmann"
    },    {
      "@type": "Person",
      "name": "Leo Kager"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases. High-grade osteosarcomas are usually treated by preoperative and postoperative chemotherapy and surgery, with a very limited number of active agents available. Rarer lower-grade variants such as parosteal and periosteal osteosarcoma or low-grade central osteosarcoma are treated by surgery only. Imaging to search for possible metastases focuses on the lung. Computed tomography is the most sensitive method but cannot reliably distinguish small metastases from benign lesions. Advances of local imaging and surgical reconstruction now allow the use of limb-salvage in an ever-increasing proportion of patients. While still troubled by complications, non-invasive endoprosthesis-lengthening mechanisms have led to an increased uptake of limb-salvage, even for young, skeletally immature patients. Radiotherapy is employed when osteosarcomas cannot be removed with clear margins, but very high doses are required, and both proton and carbon-ion radiotherapy are under investigation. Unfortunately, the past 30 years have witnessed few, if any, survival improvements. Novel agents have not led to universally accepted changes of treatment standards. In patients with operable high-grade osteosarcomas, the extent of histological response to preoperative chemotherapy is a significant predictive factor for both local and systemic control. Attempts to improve prognosis by adapting postoperative treatment to response, recently tested in a randomized, prospective setting by the European and American Osteosarcoma Study Group, have not been proven to be beneficial. Many agree that only increased knowledge about osteosarcoma biology will lead to novel, effective treatment approaches and will be able to move the field forward."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2767.html",
            "name": "Advances in the management of osteosarcoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Advances in the management of osteosarcoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10194 data-id=9465 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9465.1" data-recommended="" data-doi="10.12688/f1000research.9465.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2767/v1/pdf?article_uuid=dcd86bf4-2e40-4f2f-b441-1443c46f24c0" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9465-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9465-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9465-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bielack SS, Hecker-Nolting S, Blattmann C and Kager L. Advances in the management of osteosarcoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2767 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9465.1" target=_blank>https://doi.org/10.12688/f1000research.9465.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9465-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9465 id=track-article-signin-9465 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9465?target=/articles/5-2767.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10194 /> <input name=articleId type=hidden value=9465 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Advances in the management of osteosarcoma</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:s.bielack@klinikum-stuttgart.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Stefan S. Bielack</span></a><sup>1</sup>,&nbsp;</span><span class="">Stefanie Hecker-Nolting<sup>1</sup>,&nbsp;</span><span class="">Claudia Blattmann<sup>1</sup>,&nbsp;</span><span class="">Leo Kager<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:s.bielack@klinikum-stuttgart.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Stefan S. Bielack</span></a><sup>1</sup>,&nbsp;</span><span class="">Stefanie Hecker-Nolting<sup>1</sup>,&nbsp;</span><span class="">Claudia Blattmann<sup>1</sup>,&nbsp;</span><span class="">Leo Kager<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 25 Nov 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9465.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Klinikum Stuttgart - Olgahospital, Zentrum f&uuml;r Kinder-, Jugend- und Frauenmedizin; P&auml;diatrie 5 (Onkologie, H&auml;matologie, Immunologie), Kriegsbergstrasse 62, Stuttgart Cancer Center, Germany<br/> <sup>2</sup> St. Anna Children's Hospital, Department of Paediatrics, Medical University Vienna and Children's Cancer Research Institute CCRI, Vienna, Austria<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18252-17735></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18251-17734></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases. High-grade osteosarcomas are usually treated by preoperative and postoperative chemotherapy and surgery, with a very limited number of active agents available. Rarer lower-grade variants such as parosteal and periosteal osteosarcoma or low-grade central osteosarcoma are treated by surgery only. Imaging to search for possible metastases focuses on the lung. Computed tomography is the most sensitive method but cannot reliably distinguish small metastases from benign lesions. Advances of local imaging and surgical reconstruction now allow the use of limb-salvage in an ever-increasing proportion of patients. While still troubled by complications, non-invasive endoprosthesis-lengthening mechanisms have led to an increased uptake of limb-salvage, even for young, skeletally immature patients. Radiotherapy is employed when osteosarcomas cannot be removed with clear margins, but very high doses are required, and both proton and carbon-ion radiotherapy are under investigation. Unfortunately, the past 30 years have witnessed few, if any, survival improvements. Novel agents have not led to universally accepted changes of treatment standards. In patients with operable high-grade osteosarcomas, the extent of histological response to preoperative chemotherapy is a significant predictive factor for both local and systemic control. Attempts to improve prognosis by adapting postoperative treatment to response, recently tested in a randomized, prospective setting by the European and American Osteosarcoma Study Group, have not been proven to be beneficial. Many agree that only increased knowledge about osteosarcoma biology will lead to novel, effective treatment approaches and will be able to move the field forward. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> osteosarcoma, imaging, , surgery, chemotherapy, radiotherapy, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Stefan S. Bielack (<a href="mailto:s.bielack@klinikum-stuttgart.de">s.bielack@klinikum-stuttgart.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Stefan S. Bielack </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Stefan Bielack reports consultancy or advisory board participation for Bayer, Celgene, Clinigen, Chugai, Isofol, Lilly, Merck &amp; Co., Novartis, Pfizer, Roche, and Takeda Millennium. Leo Kager reports advisory board participation for Takeda and travel expenses for Novartis. The other authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Bielack SS <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bielack SS, Hecker-Nolting S, Blattmann C and Kager L. Advances in the management of osteosarcoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2767 (<a href="https://doi.org/10.12688/f1000research.9465.1" target=_blank>https://doi.org/10.12688/f1000research.9465.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 25 Nov 2016, <b>5</b>(F1000 Faculty Rev):2767 (<a href="https://doi.org/10.12688/f1000research.9465.1" target=_blank>https://doi.org/10.12688/f1000research.9465.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 25 Nov 2016, <b>5</b>(F1000 Faculty Rev):2767 (<a href="https://doi.org/10.12688/f1000research.9465.1" target=_blank>https://doi.org/10.12688/f1000research.9465.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e192>Introduction</h2><p class="" id=d15414e195>A 1.6–1.8-million-year-old hominin metatarsal from the South African Swartkrans paleoanthropological cave site makes osteosarcoma the earliest documented cancer of humankind<sup><a href="#ref-1">1</a></sup>. Unfortunately, the only time period since then during which significant prognostic gains were achieved was from the late 1970s until the early 1980s, when combining multi-agent chemotherapy with surgery revolutionized treatment<sup><a href="#ref-2">2</a></sup>. Unfortunately, the decades since have witnessed no further improvements of survival in North America<sup><a href="#ref-3">3</a></sup> or Europe<sup><a href="#ref-4">4</a>–<a href="#ref-6">6</a></sup>. Nevertheless, there have been numerous advances in the management of osteosarcoma which merit review and discussion.</p><p class="" id=d15414e217>Osteosarcoma is a rare bone cancer which mainly affects adolescents and young adults. Though lower-grade variants exist, most are high-grade malignancies with a high propensity for lung metastases. Current standard treatment consisting of surgery plus chemotherapy leads to long-term, disease-free survival in approximately 60% of patients with localized extremity disease<sup><a href="#ref-7">7</a>–<a href="#ref-10">10</a></sup> and 20–30% for patients with primary metastases or axial primaries<sup><a href="#ref-7">7</a>,<a href="#ref-11">11</a></sup>. Most patients are treated using a neoadjuvant approach, and histologic response to preoperative chemotherapy has emerged as an independent prognostic indicator<sup><a href="#ref-7">7</a></sup>. While combined preoperative and postoperative chemotherapy has never been shown to provide survival benefits over adjuvant chemotherapy alone (as long as both contain the same cumulative doses)<sup><a href="#ref-7">7</a>,<a href="#ref-12">12</a></sup>, it offers time to prepare for surgery and allows an <i>in vivo</i> evaluation of the effects of systemic treatment. These may be estimated by a variety of imaging methods, but histologic assessment for the proportion of viable tumor remaining at surgery is the gold standard. Patients whose primaries respond well to chemotherapy, usually defined as &lt;10% tumor viability, generally suffer fewer local<sup><a href="#ref-13">13</a></sup> and systemic<sup><a href="#ref-7">7</a>,<a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup> recurrences and achieve greater survival probabilities<sup><a href="#ref-7">7</a></sup> than others. This manuscript will try to highlight recent advances achieved in this context of first-line treatment.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e270>Advances in imaging</h2><p class="" id=d15414e273>Imaging of bone sarcomas was revolutionized by magnetic resonance imaging (MRI), which, for the first time, allowed detailed assessment of tumor extent within the bone marrow cavity and into soft tissues, as well as its relation to surrounding structures such as joints, nerves, and vessels. In addition, MRI may also be used to predict histologic tumor response to preoperative chemotherapy, as may positron emission tomography (PET)/computed tomography (CT), sequential bone scans, and others. PET/MRI has entered the scene more recently<sup><a href="#ref-14">14</a></sup>, and its role remains to be defined. The importance of accurate imaging at initial diagnosis and after preoperative chemotherapy, however, cannot be overstated. A detailed review of local imaging would be beyond the scope of this article and the reader is referred to the recent literature<sup><a href="#ref-15">15</a>–<a href="#ref-19">19</a></sup>.</p><p class="" id=d15414e287>Chest CT remains the gold standard for imaging lung metastases<sup><a href="#ref-20">20</a></sup>. Unfortunately, even modern CT scanning cannot reliably discriminate small lung metastases from small benign lesions. A recent study of 283 CT-identified lesions which led to 123 thoracotomies in 70 osteosarcoma patients found 234 of the lesions to be metastases. An additional 31, 14 of those metastases, were identified only upon thoracotomy. Lesion size ≥6 mm was suggestive for metastases, but many smaller lesions were also malignant. While most metastases were nodular and calcified, atypical findings were common<sup><a href="#ref-21">21</a></sup>. This analysis again confirms that chest CT has its limitations. Given the dire consequences associated with incomplete resection of metastatic osteosarcoma<sup><a href="#ref-11">11</a></sup>, we believe that any lung lesion detected by CT should be viewed with a high index of suspicion and treated as if it could be a metastasis. However, as highlighted by unrelated surveys among leading study groups<sup><a href="#ref-22">22</a></sup> and members of the Connective Tissue Oncology Society<sup><a href="#ref-23">23</a></sup>, the jury is still out and considerable variability surrounds the management of pulmonary lesions.</p><p class="" id=d15414e310>A minority of osteosarcomas will present with synchronous bone metastases; <sup>99m</sup>Technetium bone scans have long been part of the standard diagnostic workup. Some years ago, whole-body MRI with short time inversion recovery (STIR) imaging was found to be more sensitive for detecting bone metastases in children with suspected multifocal bone lesions than bone scans, but also less specific<sup><a href="#ref-24">24</a></sup>. Similar observations were made for PET/CT: in a recent series of 39 osteosarcomas investigated by 40 paired bone scans and PET/CTs and of whom five had bone metastases, PET/CT detected all, while bone scans missed two. On the other hand, three PET/CTs were falsely positive<sup><a href="#ref-25">25</a></sup>. It seems that histologic confirmation with a biopsy is often required before an osseous lesion suspected by whole-body STIR–MRI or PET/CT is considered a true bone metastasis but that bone scans will usually not detect additional lesions in patients investigated by either of those techniques.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e327>Advances in biopsy techniques</h2><p class="" id=d15414e330>Osteosarcoma must be confirmed histopathologically before initiating tumor-directed therapy. Biopsies were traditionally performed via incisional procedures. Even though scientists may lament a paucity of tissue for research, less invasive core needle biopsies (CNBs) are now assuming an ever-increasing role. These have been shown to be very effective as long as adequate cores can be sampled. A French analysis of CNB in 73 osteosarcomas reported an overall sensitivity of 93.1%, specificity of 100%, and positive and negative predictive values of 100% and 99.9%, respectively, as long as the specimen was adequate<sup><a href="#ref-26">26</a></sup>. CNB does not seem to be nearly as reliable in telangiectatic osteosarcoma: in one series, nine of 26 were misdiagnosed as aneurysmal bone cysts<sup><a href="#ref-27">27</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e344>Advances in local therapy of operable osteosarcoma</h2><p class="" id=d15414e347>Surgery with wide margins<sup><a href="#ref-28">28</a></sup> remains the mainstay of curative local therapy. Spurred by major advances of imaging and of surgical reconstruction opportunities, recent years have witnessed a major shift from amputations towards limb-saving procedures<sup><a href="#ref-29">29</a></sup>. Limb-salvage, however, poses challenges, particularly in growing individuals. Earlier models of expandable endoprostheses required additional surgery for every lengthening. Various non-invasive lengthening mechanisms are now available, including incorporated engines or magnetic devices<sup><a href="#ref-30">30</a></sup>. However, these are still associated with frequent complications and needs for revisions<sup><a href="#ref-31">31</a>–<a href="#ref-33">33</a></sup>. Several papers emphasize that further technical advances are direly needed: in one series, 10 patients experienced 37 implant-related complications<sup><a href="#ref-31">31</a></sup>, and in another, 42% of 38 patients experienced complications, including 10 prosthesis revisions and two amputations<sup><a href="#ref-34">34</a></sup>. A third reported an average 2.5 revisions for complications in 71 patients<sup><a href="#ref-32">32</a></sup>; a fourth even questioned whether complications associated with a particular, rather popular, expandable prosthesis were acceptable for its continued use<sup><a href="#ref-33">33</a></sup>. Given that such devices are obviously still immature, one might look back to the bygone age of rotationplasties with (never expected) nostalgia. Their function remains quite good even with long observation periods. A recent Italian series evaluated 25 patients living with rotationplasties for a mean of 15 years<sup><a href="#ref-35">35</a></sup>. While arthritis of the tibiotalar, subtalar, and talonavicular joints was radiographically present in most, they showed improved gait parameters as adults compared with previously reported findings for children with rotationplasty<sup><a href="#ref-35">35</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e397>Advances in local treatment of inoperable osteosarcomas</h2><p class="" id=d15414e400>Any osteosarcoma that can be operated on should be operated on to maximize the chance for local control and hence survival. However, not all osteosarcomas are operable. Several series have confirmed that selected patients may achieve permanent local control with radiotherapy, particularly if this is combined with effective chemotherapy and gross total resection<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. Results of a meta-analysis suggest that debulking may no longer be required when radiation doses of 70 Gy or higher are administered. Local control probabilities after radiotherapy were lower for craniofacial osteosarcomas than for those of other sites<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d15414e414>The high radiation doses required to sterilize osteosarcoma are difficult to achieve with conventional techniques, so that proton and heavy-ion radiotherapy have come into focus. In probably the largest series of 55 osteosarcomas treated with protons, the mean total radiation dose was 68.4 Gy. At 5 years, the local control rate was 72% and overall survival was 67%<sup><a href="#ref-37">37</a></sup>. Among 78 patients with inoperable osteosarcoma of the trunk irradiated with a median of 70.4 Gy carbon-ion radiotherapy (CIRT) by Japanese investigators, the 5-year local control rate was 62%<sup><a href="#ref-38">38</a></sup>. Osteosarcomas were also included in an array of sarcomas of the spine<sup><a href="#ref-39">39</a></sup> or extremities<sup><a href="#ref-40">40</a></sup> treated with CIRT. While the observed results were also encouraging, further research is required before such techniques can be considered standard. A systematic review of clinical outcome studies published between 2007 and 2015 concludes that there is insufficient evidence on the long-term effectiveness and harm of protons to either support or refute their use in children with osteosarcoma or basically any other pediatric cancer<sup><a href="#ref-41">41</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e441>Advances in systemic treatment</h2><p class="" id=d15414e444>Systemic therapy for osteosarcoma has changed very little for over 30 years and still relies on varying combinations incorporating several of the same four “old” drugs, namely high-dose methotrexate (HD-MTX), doxorubicin (Adriamycin), cisplatin, and ifosfamide<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a>,<a href="#ref-15">15</a>,<a href="#ref-42">42</a></sup>. The MAP combination of HD-MTX, doxorubicin, and cisplatin<sup><a href="#ref-43">43</a>–<a href="#ref-45">45</a></sup> is frequently used, but similar results have been achieved with other protocols employing several of the mentioned agents<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>. A meta-analysis of published osteosarcoma trials concluded that using three of the drugs led to better results than using only two but that administering all four did not lead to further improvements<sup><a href="#ref-46">46</a></sup>.</p><p class="" id=d15414e478>Several prospective trials have attempted to introduce additional agents for either all patients or certain risk groups. Some years ago, the prospective randomized INT0133 trial addressed two potential additions to MAP using a randomized two-by-two factorial design: the cytotoxic agent ifosfamide and the macrophage activator liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE, mifamurtide). A first publication<sup><a href="#ref-43">43</a></sup> as well as a second<sup><a href="#ref-44">44</a></sup> concluded that there was no benefit of adding ifosfamide. The two papers differed in their conclusions regarding L-MTP-PE: while the first stated that analysis was prevented by an interaction between ifosfamide and L-MTP-PE<sup><a href="#ref-43">43</a></sup>, the authors no longer detected a statistically significant interaction 3 years later and decided to examine each intervention separately, as originally planned. They now reported a non-significant trend toward better event-free survival (EFS) and improved overall survival with L-MTP-PE<sup><a href="#ref-44">44</a></sup>. Commentators voiced interaction concerns and questioned whether INT0133’s results met generally accepted standards for practice-changing conclusions. They called for additional clinical evaluations to define the role of the drug and to demonstrate whether any potential benefit requires concurrent use of ifosfamide<sup><a href="#ref-47">47</a></sup>. We along with others have also argued for additional randomized comparative evaluation to substantiate the utility of the drug<sup><a href="#ref-48">48</a></sup>. Since then, however, little new evidence concerning its potential efficacy has emerged. Results from the metastatic cohort of INT0133 pointed in the same direction as in non-metastatic patients but were not statistically significant<sup><a href="#ref-49">49</a></sup>. Come 2016, there is additional evidence that L-MTP-PE has a favorable safety profile: a patient access study of 200 patients reported 3,679 infusion-related adverse events after 7,482 infusions, commonly chills, fever, headache, and fatigue, but only rarely severe<sup><a href="#ref-50">50</a></sup>. However, there have been no further trials which shed more light upon the potential efficacy of the drug, so uncertainties remain regarding its potential role.</p><p class="" id=d15414e514>Another drug with immunological properties (along with many other potential mechanisms of action<sup><a href="#ref-51">51</a></sup>), interferon alpha-2b, was investigated in the largest prospectively randomized osteosarcoma study to date, the European and American Osteosarcoma Study Group (EURAMOS)-1 trial<sup><a href="#ref-45">45</a>,<a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>. A total of 716 patients whose resectable localized or primary metastatic osteosarcomas responded well to preoperative MAP were randomized after surgery to four additional cycles of MAP either with or without maintenance pegylated interferon alpha-2b<sup><a href="#ref-53">53</a></sup>. Of 357 patients randomized to receive the study drug, 271 actually started, of whom 105 stopped early. As expected, for patients whose osteosarcomas responded well to chemotherapy, 3-year EFS for all randomized patients was favorable at 76%. The hazard ratio from an adjusted Cox model was 0.83, but the 95% confidence interval (CI) included 1, meaning that MAP plus interferon alpha-2b was not statistically different from MAP alone. Interpretation of the data is, of course, complicated to a certain extent by the relevant proportion of patients who never started or who prematurely stopped interferon alpha-2b. Nevertheless, the results do not argue for its inclusion in standard osteosarcoma treatment<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d15414e539>Encouraging results with the combination of high-dose ifosfamide and etoposide were reported from phase II trials of primary or relapsed metastatic osteosarcoma<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>, so that postoperative addition of the combination to MAP (MAPIE) was investigated in the poor responder cohort of EURAMOS-1<sup><a href="#ref-45">45</a>,<a href="#ref-52">52</a></sup>. In this trial, MAPIE patients were to receive an additional three courses of 14.000 mg/m<sup>2</sup> ifosfamide with 500 mg/m<sup>2</sup> etoposide and two courses of ifosfamide at 9.000 mg/m<sup>2</sup> added to doxorubicin. MAPIE lasted 11 weeks longer than MAP. The study sought to detect absolute improvements of 10% from 45% to 55% in 3-year EFS and 5-year overall survival (hazard ratio 0.75)<sup><a href="#ref-56">56</a></sup>. Of 618 randomized patients, 310 were allocated to postoperative MAP and 308 to MAPIE; 3-year EFS rates were 55% (95% CI 49–60) and 53% (95% CI 47–59), respectively. MAPIE was more toxic and fewer patients received their intended chemotherapy doses. MAPIE was also associated with higher risk of secondary malignancy, predominantly leukemia, mostly with cytogenetic abnormalities associated with the administration of alkylating drugs (monosomy-7 or chromosome-5 abnormalities) or etoposide (11q23 abnormalities). Therefore, the EURAMOS consortium argues against adding ifosfamide and etoposide to the MAP backbone of MAP therapy for patients whose osteosarcoma shows a poor response to preoperative treatment<sup><a href="#ref-56">56</a></sup>.</p><p class="" id=d15414e575>Anyone arguing that the alkylator doses used in EURAMOS-1 were not sufficient and that high-dose chemotherapy (HDCT) with autologous blood stem cell transplant (ASCT) was a better idea should be duly cautioned by results from recent uncontrolled prospective trials: in an American study, 18 patients with newly diagnosed localized high-grade osteosarcoma and poor histologic response received HDCT/ASCT with melphalan and cyclophosphamide; 5-year EFS and overall survival were 28% and 48%, respectively<sup><a href="#ref-57">57</a></sup>. A Scandinavian–Italian study investigating postoperative high-dose carboplatin/etoposide with ASCT involved 71 patients with primary metastatic or axial osteosarcoma, of whom 29 received two and 10 one course of HDCT; 5-year EFS and overall survival were 27% and 31%, respectively. When patients not receiving HDCT owing to disease progression were excluded, there were no differences in outcomes between patients who received HDCT or not<sup><a href="#ref-58">58</a></sup>.</p><p class="" id=d15414e586>A completely different drug, the bisphosphonate zoledronate, was investigated in the prospective, randomized French multi-center OS2006 trial, which asked whether 10 courses of zoledronate added to chemotherapy and surgery might improve EFS<sup><a href="#ref-59">59</a></sup>. Chemotherapy used in this trial varied by age. Among 318 patients, 55 with primary metastases, 160 were randomized to zoledronate. The trial was stopped for futility after the second planned interim analysis when 3-year EFS was 57% for the zoledronate group and 63% for controls (p=0.094)<sup><a href="#ref-59">59</a></sup>. While the use of different chemotherapy backbones for different patients might confound interpretation to a certain degree, these results argue against zoledronate's ability to improve oncologic outcomes in osteosarcoma.</p><p class="" id=d15414e597>OS2006 as well as EURAMOS-1 exemplify that prospective randomized trials are essential to adequately assess whether treatments which show promise in the lab or in early phase studies will truly increase cure rates. They also demonstrate that such trials are feasible, even in very rare cancers such as osteosarcoma.</p><p class="" id=d15414e600>In summary, there is currently no evidence whatsoever that altering postoperative treatment in patients whose osteosarcomas respond poorly to preoperative chemotherapy or that modifying standard systemic treatment for other reasons will lead to anything but additional side effects and risks. The use of such approaches should be limited to prospective trials and otherwise discouraged.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e606>Advances in treating osteosarcoma variants</h2><p class="" id=d15414e609>While multi-modal treatment consisting of surgery and chemotherapy is the undisputed treatment standard for patients with high-grade central (arising within the affected bone) osteosarcoma of the extremities or axial skeleton, some osteosarcoma variants deserve special consideration. As for all osteosarcomas, surgery should strive to achieve wide margins. The role of additional systemic treatment, however, varies: low-grade central osteosarcoma arises within bone, just like high-grade central osteosarcoma. These tumors may carry areas of de-differentiation, and the decision to employ chemotherapy is often made based on the most malignant component. An Italian series of 132 low-grade central osteosarcomas included 33 in which high-grade (grade 3) areas were detected in the resected specimen, and postoperative chemotherapy was given to 22 of these 33. High-grade areas accounted for less than 50% in 20/33, among whom only one in nine patients not receiving chemotherapy (unrelated causes) and one in 11 receiving chemotherapy (metastatic recurrence) died. Among 13 of the 33 patients with &gt;50% grade 3 component, 12 received adjuvant chemotherapy, two had local recurrences, and four had metastatic recurrences. The only patient from this cohort treated by surgery only survived disease free<sup><a href="#ref-60">60</a></sup>. Similarly, a Norwegian nationwide cohort which included 29 low-grade central osteosarcomas, four of those with areas of de-differentiation, reported 5-year sarcoma-specific survival of 93% and confirmed that low-grade osteosarcoma has an excellent prognosis when resected with a free margin<sup><a href="#ref-61">61</a></sup>. These series suggest that low-grade osteosarcomas with small high-grade foci may still be treated by surgery only. The numbers are too small to draw conclusions for low-grade central osteosarcomas which contain larger high-grade areas.</p><p class="" id=d15414e620>Parosteal osteosarcoma is a low-grade surface osteosarcoma which may also contain high-grade areas<sup><a href="#ref-8">8</a></sup>. The already-mentioned Norwegian series also included 20 parosteal osteosarcomas, eight with signs of de-differentiation, and reported 90% 5-year sarcoma-specific survival<sup><a href="#ref-61">61</a></sup>. A retrospective British analysis of 80 parosteal osteosarcomas observed overall survival of 92% and 88% at 5 and 10 years, respectively. Local recurrences were associated with intralesional surgery, were de-differentiated in 80%, and were associated with inferior survival. The authors observed neither medullary involvement nor the use of chemotherapy to correlate with survival<sup><a href="#ref-62">62</a></sup>. One may conclude that, similar to low-grade central osteosarcoma, adequate surgery is the treatment of choice for parosteal osteosarcoma, that it is imperative to avoid local failure, and that there is no proven role for chemotherapy.</p><p class="" id=d15414e635>Periosteal osteosarcoma is a surface osteosarcoma of intermediate malignancy<sup><a href="#ref-8">8</a></sup>. While sometimes treated with chemotherapy in addition to surgery, the currently available retrospective evidence suggests that treatment should be surgery only. Corroborating similar findings from a 2005 European survey<sup><a href="#ref-63">63</a></sup>, an Italian series reported a 10-year overall survival of 84% for 33 patients, 14 of whom received chemotherapy. The authors did not find survival to be influenced by chemotherapy<sup><a href="#ref-64">64</a></sup>.</p><p class="" id=d15414e650>Craniofacial osteosarcomas carry a comparatively high local recurrence risk. The benefit of adding systemic treatments to surgery is not as well defined as for other sites, and no prospective data on adjuvant therapy has recently emerged. Nevertheless, current guidelines suggest using the same multimodal approach as for other high-grade osteosarcomas<sup><a href="#ref-65">65</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e660>Advances in follow-up</h2><p class="" id=d15414e663>Osteosarcoma recurrences may still be cured as long as they are operable<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. The aim of tumor-directed follow-up is therefore to detect local recurrences or metastases while surgery is still feasible<sup><a href="#ref-68">68</a></sup>. Surveillance usually includes chest X-rays or chest CTs in addition to history, physical, and imaging of the former primary tumor site. The wide variability of surveillance protocols actually employed is exemplified by a Musculoskeletal Tumor Society (MSTS) survey, where the number of first-year surveillance visits ranged from three to six, chest X-rays from zero to three, chest CT scans from one to four, and X-rays of the former primary site from three to six<sup><a href="#ref-69">69</a></sup>. Imaging guidelines developed by the Children’s Oncology Group (COG) suggest a schedule which heavily relies on repeated CT scanning of the lungs<sup><a href="#ref-20">20</a></sup>. However, conventional chest CT is associated with considerable radiation exposure, which led to criticism of these guidelines<sup><a href="#ref-70">70</a></sup>.</p><p class="" id=d15414e689>Several recent studies have attempted to lend more of an evidence base to osteosarcoma-directed follow-up. A retrospective single-center analysis of 101 patients with routine chest X-ray surveillance reported 34 recurrences. All eight local recurrences were noted clinically, and only two of all recurrences developed beyond 5 years. The authors propose more frequent surveillance visits during the first 2 years and chest X-ray instead of chest CT<sup><a href="#ref-68">68</a></sup>. A randomized follow-up study from India investigated 495 patients operated on for seemingly localized primary or recurrent extremity sarcomas (359 of these bone sarcomas). Chest X-ray was compared with CT scanning and 6-monthly with 3-monthly follow-up<sup><a href="#ref-71">71</a></sup>. The authors concluded that chest X-rays were not inferior to CT scans in terms of detecting pulmonary metastases and did not lead to inferior survival; 3-year overall survival was 64% with 6-monthly and 69% with 3-monthly follow-up, respectively<sup><a href="#ref-71">71</a></sup>.</p><p class="" id=d15414e704>Our interpretation of the currently available evidence is that routine follow-up for lung metastases can usually be performed with chest X-rays. Ultralow-dose CT, which limits radiation exposure to the equivalent of chest X-rays in two planes, has shown promise for lung cancer screening<sup><a href="#ref-72">72</a></sup>, so this may change should further studies demonstrate benefits for this technique in the follow-up of bone sarcoma.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e714>Future outlook</h2><p class="" id=d15414e717>Members of the generation of doctors who saw osteosarcoma cure rates rise within their professional lifetimes have by now reached retirement or are close. How do we move forward? The optimal “conventional” chemotherapy regimen remains to be defined, and efforts to identify additional effective cytotoxic combinations, as exemplified by the demonstration of activity for the gemcitabine/docetaxel combination<sup><a href="#ref-73">73</a></sup>, or to augment the usability of known effective agents by mitigating toxicities, exemplified by adding the cardioprotective agent dexrazoxane to increase doxorubicin exposure<sup><a href="#ref-74">74</a></sup>, are ongoing. It would be very optimistic to expect anything but limited improvements from such approaches.</p><p class="" id=d15414e728>Like in most other cancers, immunotherapy and the so-called targeted therapies are current hot topics<sup><a href="#ref-75">75</a>–<a href="#ref-78">78</a></sup>. As exemplified in 29 patients with refractory/relapsed osteosarcomas registered between 2009 and 2013 within the French Sarcoma Group–Bone Tumor Study Group (GSF–GETO) who received 33 treatment lines of targeted therapies, off-label use is already quite common<sup><a href="#ref-79">79</a></sup>. Prospective trials will be essential to define their role or that of any other new treatments which may arise.</p><p class="" id=d15414e742>Unfortunately, osteosarcoma tumor matrix often prevents capturing the effects of investigational treatments by conventional radiologic Response Evaluation Criteria In Solid Tumors (RECIST): lesions simply cannot shrink, even if the tumor cells are killed. Accordingly, a retrospective analysis of seven COG osteosarcoma phase II trials found all drugs inactive on the basis of radiographic response<sup><a href="#ref-80">80</a></sup>. Other trial designs and endpoints have been called for<sup><a href="#ref-81">81</a></sup>, and COG has constructed baseline EFS outcomes – including 12% EFS at 4 months for patients with measurable recurrent or refractory disease – that could be used as comparators for future phase II trials<sup><a href="#ref-80">80</a></sup>. EFS-based outcomes have already been employed in sequential phase II trials of sorafenib given alone<sup><a href="#ref-82">82</a></sup> or in combination with everolimus<sup><a href="#ref-83">83</a></sup> and have demonstrated some activity. Antagonists of the insulin-like growth factor type-1 receptor (IGF1R) are examples of other agents which have shown limited activity in several trials<sup><a href="#ref-84">84</a>,<a href="#ref-85">85</a></sup>; however, their development was more or less terminated after they failed in common cancers.</p><p class="" id=d15414e773>Both sorafenib and IGF1R inhibitors were tested because the focus of osteosarcoma research has shifted towards gaining a better understanding of the driving forces behind tumor development and progression and then hypothesis-driven drug discovery and development<sup><a href="#ref-86">86</a></sup>. The identification of the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway as a central vulnerability for therapeutic exploitation and subsequent detection of responsiveness of osteosarcoma cell lines to PI3K/mTOR inhibition<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup> or the detection of BRCAness in a substantial subset of osteosarcomas<sup><a href="#ref-89">89</a></sup> with the subsequent demonstration of susceptibility of osteosarcoma cells with a BRCAness signature to poly(ADP-ribose) polymerase (PARP) inhibition<sup><a href="#ref-90">90</a></sup> may serve as current examples of preclinical endeavors which deserve clinical evaluation.</p><p class="" id=d15414e796>It can only be hoped for that not only will we manage to learn more about the biology of osteosarcoma but also this will lead to further steps towards its eradication. Only time, dedicated pre-clinical research, and well-designed clinical trials will tell.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15414e802>Abbreviations</h2><p class="" id=d15414e805>ASCT, autologous blood stem cell transplant; CI, confidence interval; CIRT, carbon-ion radiotherapy; COG, Children’s Oncology Group; CNB, core needle biopsy; CT, computed tomography; EFS, event-free survival; EURAMOS, European and American Osteosarcoma Study Group; HDCT, high-dose chemotherapy; HD-MTX, high-dose methotrexate; IGF1R, insulin-like growth factor type-1 receptor; L-MTP-PE, liposomal muramyl tripeptide phosphatidylethanolamine; MAP, methotrexate, Adriamycin, and cisplatin; MAPIE, methotrexate, Adriamycin, cisplatin, ifosfamide, and etoposide; MRI, magnetic resonance imaging; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PET, positron emission tomography; STIR, short time inversion recovery.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d15414e1 class=n-a></a><h2 class=main-title id=d15700>Competing interests</h2><p class=metadata-entry><a name=d15414e127 class=n-a></a><p id=d15414e129> Stefan Bielack reports consultancy or advisory board participation for Bayer, Celgene, Clinigen, Chugai, Isofol, Lilly, Merck &amp; Co., Novartis, Pfizer, Roche, and Takeda Millennium. Leo Kager reports advisory board participation for Takeda and travel expenses for Novartis. The other authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d15414e1 class=n-a></a><h2 class=main-title id=d15702>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d15414e812 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d16005>References</h2><div class="section ref-list"><a name=d15414e812 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d15414e819 class=n-a></a>Odes EJ, Randolph-Quinney PS, Steyn M, <i> et al.</i>: Earliest hominin cancer: 1.7-million-year-old osteosarcoma from Swartkrans Cave, South Africa. <i>S Afr J Sci.</i> 2016; <b>112</b>: 5. <a target=xrefwindow id=d15414e830 href="http://dx.doi.org/10.17159/sajs.2016/20150471">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d15414e839 class=n-a></a>Jaffe N, Puri A, Gelderblom H: Osteosarcoma: evolution of treatment paradigms. <i>Sarcoma.</i> 2013; <b>2013</b>: 203531. <a target=xrefwindow id=d15414e847 href="http://www.ncbi.nlm.nih.gov/pubmed/23781130">PubMed Abstract </a> | <a target=xrefwindow id=d15414e850 href="http://dx.doi.org/10.1155/2013/203531">Publisher Full Text </a> | <a target=xrefwindow id=d15414e853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3678494">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d15414e862 class=n-a></a>Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. <i>Cancer.</i> 2009; <b>115</b>(7): 1531–43. <a target=xrefwindow id=d15414e870 href="http://www.ncbi.nlm.nih.gov/pubmed/19197972">PubMed Abstract </a> | <a target=xrefwindow id=d15414e873 href="http://dx.doi.org/10.1002/cncr.24121">Publisher Full Text </a> | <a target=xrefwindow id=d15414e876 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2813207">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d15414e885 class=n-a></a>Stiller CA, Bielack SS, Jundt G, <i> et al.</i>: Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. <i>Eur J Cancer.</i> 2006; <b>42</b>(13): 2124–35. <a target=xrefwindow id=d15414e896 href="http://www.ncbi.nlm.nih.gov/pubmed/16919776">PubMed Abstract </a> | <a target=xrefwindow id=d15414e899 href="http://dx.doi.org/10.1016/j.ejca.2006.05.015">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d15414e908 class=n-a></a>Gatta G, Botta L, Rossi S, <i> et al.</i>: Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5--a population-based study. <i>Lancet Oncol.</i> 2014; <b>15</b>(1): 35–47. <a target=xrefwindow id=d15414e919 href="http://www.ncbi.nlm.nih.gov/pubmed/24314616">PubMed Abstract </a> | <a target=xrefwindow id=d15414e922 href="http://dx.doi.org/10.1016/S1470-2045(13)70548-5">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d15414e932 class=n-a></a>Berner K, Johannesen TB, Berner A, <i> et al.</i>: Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. <i>Acta Oncol.</i> 2015; <b>54</b>(1): 25–33. <a target=xrefwindow id=d15414e943 href="http://www.ncbi.nlm.nih.gov/pubmed/24957555">PubMed Abstract </a> | <a target=xrefwindow id=d15414e946 href="http://dx.doi.org/10.3109/0284186X.2014.923934">Publisher Full Text </a> | <a target=xrefwindow id=d15414e950 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4364276">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d15414e959 class=n-a></a>Bielack SS, Kempf-Bielack B, Delling G, <i> et al.</i>: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. <i>J Clin Oncol.</i> 2002; <b>20</b>(3): 776–90. <a target=xrefwindow id=d15414e970 href="http://www.ncbi.nlm.nih.gov/pubmed/11821461">PubMed Abstract </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d15414e979 class=n-a></a>Fletcher CDM, Bridge JA, Hogendoorn P, <i> et al.</i>: WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. World Health Organization, WHO Press, Geneva, 2013; <b>5</b>(5). <a target=xrefwindow id=d15414e987 href="http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&amp;codcol=70&amp;codcch=4005">Reference Source</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d15414e996 class=n-a></a>Bielack S, Kempf-Bielack B, von Kalle T, <i> et al.</i>: Controversies in childhood osteosarcoma. <i>Minerva Pediatr.</i> 2013; <b>65</b>(2): 125–48. <a target=xrefwindow id=d15414e1007 href="http://www.ncbi.nlm.nih.gov/pubmed/23612259">PubMed Abstract </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726965118"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1016 class=n-a></a>Ferrari S, Serra M: An update on chemotherapy for osteosarcoma. <i>Expert Opin Pharmacother.</i> 2015; <b>16</b>(18): 2727–36. <a target=xrefwindow id=d15414e1024 href="http://www.ncbi.nlm.nih.gov/pubmed/26512909">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1027 href="http://dx.doi.org/10.1517/14656566.2015.1102226">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726965118">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d15414e1040 class=n-a></a>Kager L, Zoubek A, Potschger U, <i> et al.</i>: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. <i>J Clin Oncol.</i> 2003; <b>21</b>(10): 2011–8. <a target=xrefwindow id=d15414e1051 href="http://www.ncbi.nlm.nih.gov/pubmed/12743156">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1054 href="http://dx.doi.org/10.1200/JCO.2003.08.132">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d15414e1064 class=n-a></a>Goorin AM, Schwartzentruber DJ, Devidas M, <i> et al.</i>: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. <i>J Clin Oncol.</i> 2003; <b>21</b>(8): 1574–80. <a target=xrefwindow id=d15414e1075 href="http://www.ncbi.nlm.nih.gov/pubmed/12697883">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1078 href="http://dx.doi.org/10.1200/JCO.2003.08.165">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d15414e1087 class=n-a></a>Andreou D, Bielack SS, Carrle D, <i> et al.</i>: The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. <i>Ann Oncol.</i> 2011; <b>22</b>(5): 1228–35. <a target=xrefwindow id=d15414e1098 href="http://www.ncbi.nlm.nih.gov/pubmed/21030381">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1101 href="http://dx.doi.org/10.1093/annonc/mdq589">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726276586"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1110 class=n-a></a>Chaudhry AA, Gul M, Gould E, <i> et al.</i>: Utility of positron emission tomography-magnetic resonance imaging in musculoskeletal imaging. <i>World J Radiol.</i> 2016; <b>8</b>(3): 268–74. <a target=xrefwindow id=d15414e1121 href="http://www.ncbi.nlm.nih.gov/pubmed/27027320">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1124 href="http://dx.doi.org/10.4329/wjr.v8.i3.268">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1128 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4807335">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726276586">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d15414e1141 class=n-a></a>Kaste SC: Imaging pediatric bone sarcomas. <i>Radiol Clin North Am.</i> 2011; <b>49</b>(4): 749–65, vi–vii. <a target=xrefwindow id=d15414e1149 href="http://www.ncbi.nlm.nih.gov/pubmed/21807172">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1152 href="http://dx.doi.org/10.1016/j.rcl.2011.05.006">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1155 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4725719">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d15414e1164 class=n-a></a>Bancroft LW: Postoperative tumor imaging. <i>Semin Musculoskelet Radiol.</i> 2011; <b>15</b>(4): 425–38. <a target=xrefwindow id=d15414e1172 href="http://www.ncbi.nlm.nih.gov/pubmed/21928163">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1175 href="http://dx.doi.org/10.1055/s-0031-1286020">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d15414e1184 class=n-a></a>Garner HW, Kransdorf MJ, Peterson JJ: Posttherapy imaging of musculoskeletal neoplasms. <i>Radiol Clin North Am.</i> 2011; <b>49</b>(6): 1307–23, vii. <a target=xrefwindow id=d15414e1192 href="http://www.ncbi.nlm.nih.gov/pubmed/22024300">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1195 href="http://dx.doi.org/10.1016/j.rcl.2011.07.011">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d15414e1205 class=n-a></a>Fox MG, Trotta BM: Osteosarcoma: review of the various types with emphasis on recent advancements in imaging. <i>Semin Musculoskelet Radiol.</i> 2013; <b>17</b>(2): 123–36. <a target=xrefwindow id=d15414e1213 href="http://www.ncbi.nlm.nih.gov/pubmed/23673544">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1216 href="http://dx.doi.org/10.1055/s-0033-1342969">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d15414e1225 class=n-a></a>Kubo T, Furuta T, Johan MP, <i> et al.</i>: Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis. <i>Skeletal Radiol.</i> 2016; <b>45</b>(9): 1235–42. <a target=xrefwindow id=d15414e1236 href="http://www.ncbi.nlm.nih.gov/pubmed/27229874">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1239 href="http://dx.doi.org/10.1007/s00256-016-2410-y">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d15414e1248 class=n-a></a>Meyer JS, Nadel HR, Marina N, <i> et al.</i>: Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. <i>Pediatr Blood Cancer.</i> 2008; <b>51</b>(2): 163–70. <a target=xrefwindow id=d15414e1259 href="http://www.ncbi.nlm.nih.gov/pubmed/18454470">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1262 href="http://dx.doi.org/10.1002/pbc.21596">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725854706"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1271 class=n-a></a>Ciccarese F, Bazzocchi A, Ciminari R, <i> et al.</i>: The many faces of pulmonary metastases of osteosarcoma: Retrospective study on 283 lesions submitted to surgery. <i>Eur J Radiol.</i> 2015; <b>84</b>(12): 2679–85. <a target=xrefwindow id=d15414e1282 href="http://www.ncbi.nlm.nih.gov/pubmed/26472138">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1285 href="http://dx.doi.org/10.1016/j.ejrad.2015.09.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725854706">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d15414e1298 class=n-a></a>Carrle D, Bielack S: Osteosarcoma lung metastases detection and principles of multimodal therapy. <i>Cancer Treat Res.</i> 2009; <b>152</b>: 165–84. <a target=xrefwindow id=d15414e1306 href="http://www.ncbi.nlm.nih.gov/pubmed/20213390">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1309 href="http://dx.doi.org/10.1007/978-1-4419-0284-9_8">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d15414e1318 class=n-a></a>Bhattasali O, Vo AT, Roth M, <i> et al.</i>: Variability in the reported management of pulmonary metastases in osteosarcoma. <i>Cancer Med.</i> 2015; <b>4</b>(4): 523–31. <a target=xrefwindow id=d15414e1329 href="http://www.ncbi.nlm.nih.gov/pubmed/25626877">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1332 href="http://dx.doi.org/10.1002/cam4.407">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1336 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4402067">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d15414e1346 class=n-a></a>Mentzel HJ, Kentouche K, Sauner D, <i> et al.</i>: Comparison of whole-body STIR-MRI and <sup>99m</sup>Tc-methylene-diphosphonate scintigraphy in children with suspected multifocal bone lesions. <i>Eur Radiol.</i> 2004; <b>14</b>(12): 2297–302. <a target=xrefwindow id=d15414e1360 href="http://www.ncbi.nlm.nih.gov/pubmed/15243716">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1364 href="http://dx.doi.org/10.1007/s00330-004-2390-5">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726290282"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1373 class=n-a></a>Hurley C, McCarville MB, Shulkin BL, <i> et al.</i>: Comparison of <sup>18</sup>F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(8): 1381–6. <a target=xrefwindow id=d15414e1387 href="http://www.ncbi.nlm.nih.gov/pubmed/27082077">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1391 href="http://dx.doi.org/10.1002/pbc.26014">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1394 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5082741">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726290282">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726965132"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1407 class=n-a></a>Taupin T, Decouvelaere AV, Vaz G, <i> et al.</i>: Accuracy of core needle biopsy for the diagnosis of osteosarcoma: A retrospective analysis of 73 patients. <i>Diagn Interv Imaging.</i> 2016; <b>97</b>(3): 327–31. <a target=xrefwindow id=d15414e1418 href="http://www.ncbi.nlm.nih.gov/pubmed/26616843">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1421 href="http://dx.doi.org/10.1016/j.diii.2015.09.013">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726965132">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d15414e1434 class=n-a></a>Gao ZH, Yin JQ, Liu DW, <i> et al.</i>: Preoperative easily misdiagnosed telangiectatic osteosarcoma: clinical-radiologic-pathologic correlations. <i>Cancer Imaging.</i> 2013; <b>13</b>(4): 520–6. <a target=xrefwindow id=d15414e1445 href="http://www.ncbi.nlm.nih.gov/pubmed/24334494">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1448 href="http://dx.doi.org/10.1102/1470-7330.2013.0042">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1452 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3864225">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d15414e1461 class=n-a></a>Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. <i>Clin Orthop Relat Res.</i> 1980; (153): 106–20. <a target=xrefwindow id=d15414e1466 href="http://www.ncbi.nlm.nih.gov/pubmed/7449206">PubMed Abstract </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d15414e1475 class=n-a></a>Bielack S, Jürgens H, Jundt G, <i> et al.</i>: Osteosarcoma: the COSS experience. <i>Cancer Treat Res.</i> 2009; <b>152</b>: 289–308. <a target=xrefwindow id=d15414e1486 href="http://www.ncbi.nlm.nih.gov/pubmed/20213397">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1489 href="http://dx.doi.org/10.1007/978-1-4419-0284-9_15">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d15414e1499 class=n-a></a>Nystrom LM, Morcuende JA: Expanding endoprosthesis for pediatric musculoskeletal malignancy: current concepts and results. <i>Iowa Orthop J.</i> 2010; <b>30</b>: 141–9. <a target=xrefwindow id=d15414e1507 href="http://www.ncbi.nlm.nih.gov/pubmed/21045986">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2958285">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718323801"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1519 class=n-a></a>Cipriano CA, Gruzinova IS, Frank RM, <i> et al.</i>: Frequent complications and severe bone loss associated with the repiphysis expandable distal femoral prosthesis. <i>Clin Orthop Relat Res.</i> 2015; <b>473</b>(3): 831–8. <a target=xrefwindow id=d15414e1530 href="http://www.ncbi.nlm.nih.gov/pubmed/24664193">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1533 href="http://dx.doi.org/10.1007/s11999-014-3564-3">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1537 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4317465">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718323801">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725840041"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1550 class=n-a></a>Schinhan M, Tiefenboeck T, Funovics P, <i> et al.</i>: Extendible Prostheses for Children After Resection of Primary Malignant Bone Tumor: Twenty-seven Years of Experience. <i>J Bone Joint Surg Am.</i> 2015; <b>97</b>(19): 1585–91. <a target=xrefwindow id=d15414e1561 href="http://www.ncbi.nlm.nih.gov/pubmed/26446966">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1564 href="http://dx.doi.org/10.2106/JBJS.N.00892">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725840041">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725511013"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1577 class=n-a></a>Staals EL, Colangeli M, Ali N, <i> et al.</i>: Are Complications Associated With the Repiphysis<sup>®</sup> Expandable Distal Femoral Prosthesis Acceptable for Its Continued Use? <i>Clin Orthop Relat Res.</i> 2015; <b>473</b>(9): 3003–13. <a target=xrefwindow id=d15414e1591 href="http://www.ncbi.nlm.nih.gov/pubmed/25995179">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1595 href="http://dx.doi.org/10.1007/s11999-015-4355-1">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1598 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4523511">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725511013">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d15414e1611 class=n-a></a>Henderson ER, Pepper AM, Marulanda G, <i> et al.</i>: Outcome of lower-limb preservation with an expandable endoprosthesis after bone tumor resection in children. <i>J Bone Joint Surg Am.</i> 2012; <b>94</b>(6): 537–47. <a target=xrefwindow id=d15414e1622 href="http://www.ncbi.nlm.nih.gov/pubmed/22438003">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1625 href="http://dx.doi.org/10.2106/JBJS.I.01575">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d15414e1634 class=n-a></a>Benedetti MG, Okita Y, Recubini E, <i> et al.</i>: How Much Clinical and Functional Impairment do Children Treated With Knee Rotationplasty Experience in Adulthood? <i>Clin Orthop Relat Res.</i> 2016; <b>474</b>(4): 995–1004. <a target=xrefwindow id=d15414e1645 href="http://www.ncbi.nlm.nih.gov/pubmed/26754115">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1648 href="http://dx.doi.org/10.1007/s11999-016-4691-9">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1652 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4773340">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d15414e1662 class=n-a></a>Schwarz R, Bruland O, Cassoni A, <i> et al.</i>: The role of radiotherapy in osteosarcoma. <i>Cancer Treat Res.</i> 2009; <b>152</b>: 147–64. <a target=xrefwindow id=d15414e1673 href="http://www.ncbi.nlm.nih.gov/pubmed/20213389">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1676 href="http://dx.doi.org/10.1007/978-1-4419-0284-9_7">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/723442033"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1685 class=n-a></a>Ciernik IF, Niemierko A, Harmon DC, <i> et al.</i>: Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. <i>Cancer.</i> 2011; <b>117</b>(19): 4522–30. <a target=xrefwindow id=d15414e1696 href="http://www.ncbi.nlm.nih.gov/pubmed/21448934">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1699 href="http://dx.doi.org/10.1002/cncr.26037">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1703 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3716000">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/723442033">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d15414e1716 class=n-a></a>Matsunobu A, Imai R, Kamada T, <i> et al.</i>: Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. <i>Cancer.</i> 2012; <b>118</b>(18): 4555–63. <a target=xrefwindow id=d15414e1727 href="http://www.ncbi.nlm.nih.gov/pubmed/22359113">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1730 href="http://dx.doi.org/10.1002/cncr.27451">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d15414e1739 class=n-a></a>Matsumoto K, Imai R, Kamada T, <i> et al.</i>: Impact of carbon ion radiotherapy for primary spinal sarcoma. <i>Cancer.</i> 2013; <b>119</b>(19): 3496–503. <a target=xrefwindow id=d15414e1750 href="http://www.ncbi.nlm.nih.gov/pubmed/23939877">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1753 href="http://dx.doi.org/10.1002/cncr.28177">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d15414e1762 class=n-a></a>Sugahara S, Kamada T, Imai R, <i> et al.</i>: Carbon ion radiotherapy for localized primary sarcoma of the extremities: results of a phase I/II trial. <i>Radiother Oncol.</i> 2012; <b>105</b>(2): 226–31. <a target=xrefwindow id=d15414e1773 href="http://www.ncbi.nlm.nih.gov/pubmed/23068710">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1776 href="http://dx.doi.org/10.1016/j.radonc.2012.09.010">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726291455"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1785 class=n-a></a>Leroy R, Benahmed N, Hulstaert F, <i> et al.</i>: Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. <i>Int J Radiat Oncol Biol Phys.</i> 2016; <b>95</b>(1): 267–78. <a target=xrefwindow id=d15414e1796 href="http://www.ncbi.nlm.nih.gov/pubmed/27084646">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1799 href="http://dx.doi.org/10.1016/j.ijrobp.2015.10.025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726291455">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d15414e1813 class=n-a></a>Isakoff MS, Bielack SS, Meltzer P, <i> et al.</i>: Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. <i>J Clin Oncol.</i> 2015; <b>33</b>(27): 3029–35. <a target=xrefwindow id=d15414e1824 href="http://www.ncbi.nlm.nih.gov/pubmed/26304877">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1827 href="http://dx.doi.org/10.1200/JCO.2014.59.4895">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1831 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4979196">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d15414e1840 class=n-a></a>Meyers PA, Schwartz CL, Krailo M, <i> et al.</i>: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. <i>J Clin Oncol.</i> 2005; <b>23</b>(9): 2004–11. <a target=xrefwindow id=d15414e1851 href="http://www.ncbi.nlm.nih.gov/pubmed/15774791">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1854 href="http://dx.doi.org/10.1200/JCO.2005.06.031">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1099371"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e1863 class=n-a></a>Meyers PA, Schwartz CL, Krailo MD, <i> et al.</i>: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. <i>J Clin Oncol.</i> 2008; <b>26</b>(4): 633–8. <a target=xrefwindow id=d15414e1874 href="http://www.ncbi.nlm.nih.gov/pubmed/18235123">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1877 href="http://dx.doi.org/10.1200/JCO.2008.14.0095">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1099371">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d15414e1890 class=n-a></a>Whelan JS, Bielack SS, Marina N, <i> et al.</i>: EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. <i>Ann Oncol.</i> 2015; <b>26</b>(2): 407–14. <a target=xrefwindow id=d15414e1901 href="http://www.ncbi.nlm.nih.gov/pubmed/25421877">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1904 href="http://dx.doi.org/10.1093/annonc/mdu526">Publisher Full Text </a> | <a target=xrefwindow id=d15414e1908 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4304379">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d15414e1917 class=n-a></a>Anninga JK, Gelderblom H, Fiocco M, <i> et al.</i>: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? <i>Eur J Cancer.</i> 2011; <b>47</b>(16): 2431–45. <a target=xrefwindow id=d15414e1928 href="http://www.ncbi.nlm.nih.gov/pubmed/21703851">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1931 href="http://dx.doi.org/10.1016/j.ejca.2011.05.030">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d15414e1940 class=n-a></a>Hunsberger S, Freidlin B, Smith MA: Complexities in interpretation of osteosarcoma clinical trial results. <i>J Clin Oncol.</i> 2008; <b>26</b>(18): 3103–4; author reply 3104–5. <a target=xrefwindow id=d15414e1948 href="http://www.ncbi.nlm.nih.gov/pubmed/18565905">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1951 href="http://dx.doi.org/10.1200/JCO.2008.17.3484">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d15414e1961 class=n-a></a>Bielack SS, Marina N, Ferrari S, <i> et al.</i>: Osteosarcoma: the same old drugs or more? <i>J Clin Oncol.</i> 2008; <b>26</b>(18): 3102–3; author reply 3104–5. <a target=xrefwindow id=d15414e1972 href="http://www.ncbi.nlm.nih.gov/pubmed/18565904">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1975 href="http://dx.doi.org/10.1200/JCO.2008.17.1108">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d15414e1984 class=n-a></a>Chou AJ, Kleinerman ES, Krailo MD, <i> et al.</i>: Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. <i>Cancer.</i> 2009; <b>115</b>(22): 5339–48. <a target=xrefwindow id=d15414e1995 href="http://www.ncbi.nlm.nih.gov/pubmed/19637348">PubMed Abstract </a> | <a target=xrefwindow id=d15414e1998 href="http://dx.doi.org/10.1002/cncr.24566">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2002 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2783515">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d15414e2011 class=n-a></a>Anderson PM, Meyers P, Kleinerman E, <i> et al.</i>: Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. <i>Pediatr Blood Cancer.</i> 2014; <b>61</b>(2): 238–44. <a target=xrefwindow id=d15414e2022 href="http://www.ncbi.nlm.nih.gov/pubmed/23997016">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2025 href="http://dx.doi.org/10.1002/pbc.24686">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2029 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4533988">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d15414e2038 class=n-a></a>Whelan J, Patterson D, Perisoglou M, <i> et al.</i>: The role of interferons in the treatment of osteosarcoma. <i>Pediatr Blood Cancer.</i> 2010; <b>54</b>(3): 350–4. <a target=xrefwindow id=d15414e2049 href="http://www.ncbi.nlm.nih.gov/pubmed/19902521">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2052 href="http://dx.doi.org/10.1002/pbc.22136">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d15414e2061 class=n-a></a>Marina N, Bielack S, Whelan J, <i> et al.</i>: International collaboration is feasible in trials for rare conditions: the EURAMOS experience. <i>Cancer Treat Res.</i> 2009; <b>152</b>: 339–53. <a target=xrefwindow id=d15414e2072 href="http://www.ncbi.nlm.nih.gov/pubmed/20213400">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2075 href="http://dx.doi.org/10.1007/978-1-4419-0284-9_18">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d15414e2084 class=n-a></a>Bielack SS, Smeland S, Whelan JS, <i> et al.</i>: Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>J Clin Oncol.</i> 2015; <b>33</b>(20): 2279–87. <a target=xrefwindow id=d15414e2095 href="http://www.ncbi.nlm.nih.gov/pubmed/26033801">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2098 href="http://dx.doi.org/10.1200/JCO.2014.60.0734">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2102 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4486345">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d15414e2112 class=n-a></a>Gentet JC, Brunat-Mentigny M, Demaille MC, <i> et al.</i>: Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. <i>Eur J Cancer.</i> 1997; <b>33</b>(2): 232–7. <a target=xrefwindow id=d15414e2123 href="http://www.ncbi.nlm.nih.gov/pubmed/9135494">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2126 href="http://dx.doi.org/10.1016/S0959-8049(96)00439-X">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d15414e2135 class=n-a></a>Goorin AM, Harris MB, Bernstein M, <i> et al.</i>: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. <i>J Clin Oncol.</i> 2002; <b>20</b>(2): 426–33. <a target=xrefwindow id=d15414e2146 href="http://www.ncbi.nlm.nih.gov/pubmed/11786570">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2149 href="http://dx.doi.org/10.1200/JCO.20.2.426">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d15414e2158 class=n-a></a>Marina NM, Smeland S, Bielack SS, <i> et al.</i>: Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(10): 1396–1408. <a target=xrefwindow id=d15414e2169 href="http://www.ncbi.nlm.nih.gov/pubmed/27569442">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2172 href="http://dx.doi.org/10.1016/S1470-2045(16)30214-5">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5052459">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725878467"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2185 class=n-a></a>Venkatramani R, Murray J, Helman L, <i> et al.</i>: Risk-Based Therapy for Localized Osteosarcoma. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(3): 412–7. <a target=xrefwindow id=d15414e2196 href="http://www.ncbi.nlm.nih.gov/pubmed/26501936">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2199 href="http://dx.doi.org/10.1002/pbc.25808">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725878467">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718181826"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2212 class=n-a></a>Boye K, Del Prever AB, Eriksson M, <i> et al.</i>: High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study. <i>Pediatr Blood Cancer.</i> 2014; <b>61</b>(5): 840–5. <a target=xrefwindow id=d15414e2223 href="http://www.ncbi.nlm.nih.gov/pubmed/24254749">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2226 href="http://dx.doi.org/10.1002/pbc.24868">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718181826">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726438889"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2239 class=n-a></a>Piperno-Neumann S, Le Deley MC, Rédini F, <i> et al.</i>: Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(8): 1070–80. <a target=xrefwindow id=d15414e2250 href="http://www.ncbi.nlm.nih.gov/pubmed/27324280">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2253 href="http://dx.doi.org/10.1016/S1470-2045(16)30096-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726438889">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726965188"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2267 class=n-a></a>Righi A, Paioli A, Dei Tos AP, <i> et al.</i>: High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma? <i>Clin Sarcoma Res.</i> 2015; <b>5</b>: 23. <a target=xrefwindow id=d15414e2278 href="http://www.ncbi.nlm.nih.gov/pubmed/26524981">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2281 href="http://dx.doi.org/10.1186/s13569-015-0038-7">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2285 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4627618">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726965188">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726965193"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2298 class=n-a></a>Berner K, Johannesen TB, Bruland OS: Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009. <i>Sarcoma.</i> 2015; <b>2015</b>: 917679. <a target=xrefwindow id=d15414e2306 href="http://www.ncbi.nlm.nih.gov/pubmed/26412976">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2309 href="http://dx.doi.org/10.1155/2015/917679">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2312 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4568035">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726965193">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726965196"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2325 class=n-a></a>Laitinen M, Parry M, Albergo JI, <i> et al.</i>: The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. <i>Bone Joint J.</i> 2015; <b>97-B</b>(12): 1698–703. <a target=xrefwindow id=d15414e2336 href="http://www.ncbi.nlm.nih.gov/pubmed/26637687">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2339 href="http://dx.doi.org/10.1302/0301-620X.97B12.35749">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726965196">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d15414e2352 class=n-a></a>Grimer RJ, Bielack S, Flege S, <i> et al.</i>: Periosteal osteosarcoma--a European review of outcome. <i>Eur J Cancer.</i> 2005; <b>41</b>(18): 2806–11. <a target=xrefwindow id=d15414e2363 href="http://www.ncbi.nlm.nih.gov/pubmed/16290134">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2366 href="http://dx.doi.org/10.1016/j.ejca.2005.04.052">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d15414e2375 class=n-a></a>Cesari M, Alberghini M, Vanel D, <i> et al.</i>: Periosteal osteosarcoma: a single-institution experience. <i>Cancer.</i> 2011; <b>117</b>(8): 1731–5. <a target=xrefwindow id=d15414e2386 href="http://www.ncbi.nlm.nih.gov/pubmed/21472720">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2389 href="http://dx.doi.org/10.1002/cncr.25718">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d15414e2398 class=n-a></a>ESMO/European Sarcoma Network Working Group: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2014; <b>25</b>(Suppl 3): iii113–23. <a target=xrefwindow id=d15414e2406 href="http://www.ncbi.nlm.nih.gov/pubmed/25210081">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2409 href="http://dx.doi.org/10.1093/annonc/mdu256">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d15414e2419 class=n-a></a>Kempf-Bielack B, Bielack SS, Jürgens H, <i> et al.</i>: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). <i>J Clin Oncol.</i> 2005; <b>23</b>(3): 559–68. <a target=xrefwindow id=d15414e2430 href="http://www.ncbi.nlm.nih.gov/pubmed/15659502">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2433 href="http://dx.doi.org/10.1200/JCO.2005.04.063">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1159231"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2442 class=n-a></a>Bielack SS, Kempf-Bielack B, Branscheid D, <i> et al.</i>: Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. <i>J Clin Oncol.</i> 2009; <b>27</b>(4): 557–65. <a target=xrefwindow id=d15414e2453 href="http://www.ncbi.nlm.nih.gov/pubmed/19075282">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2456 href="http://dx.doi.org/10.1200/JCO.2008.16.2305">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1159231">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726339549"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2469 class=n-a></a>Rothermundt C, Seddon BM, Dileo P, <i> et al.</i>: Follow-up practices for high-grade extremity Osteosarcoma. <i>BMC Cancer.</i> 2016; <b>16</b>: 301. <a target=xrefwindow id=d15414e2480 href="http://www.ncbi.nlm.nih.gov/pubmed/27154292">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2483 href="http://dx.doi.org/10.1186/s12885-016-2333-y">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2487 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4859955">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726339549">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726965200"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2500 class=n-a></a>Greenberg DD, Crawford B: Surveillance Strategies for Sarcoma: Results of a Survey of Members of the Musculoskeletal Tumor Society. <i>Sarcoma.</i> 2016; <b>2016</b>: 8289509. <a target=xrefwindow id=d15414e2508 href="http://www.ncbi.nlm.nih.gov/pubmed/27478404">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2511 href="http://dx.doi.org/10.1155/2016/8289509">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2514 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4961806">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726965200">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d15414e2527 class=n-a></a>Dauer LT, St Germain J, Meyers PA: Let's image gently: reducing excessive reliance on CT scans. <i>Pediatr Blood Cancer.</i> 2008; <b>51</b>(6): 838; author reply 839–40. <a target=xrefwindow id=d15414e2535 href="http://www.ncbi.nlm.nih.gov/pubmed/18802945">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2538 href="http://dx.doi.org/10.1002/pbc.21725">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718180784"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2547 class=n-a></a>Puri A, Gulia A, Hawaldar R, <i> et al.</i>: Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. <i>Clin Orthop Relat Res.</i> 2014; <b>472</b>(5): 1568–75. <a target=xrefwindow id=d15414e2558 href="http://www.ncbi.nlm.nih.gov/pubmed/24249538">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2561 href="http://dx.doi.org/10.1007/s11999-013-3385-9">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2565 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3971232">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718180784">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726104848"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2579 class=n-a></a>Huber A, Landau J, Ebner L, <i> et al.</i>: Performance of ultralow-dose CT with iterative reconstruction in lung cancer screening: limiting radiation exposure to the equivalent of conventional chest X-ray imaging. <i>Eur Radiol.</i> 2016; <b>26</b>(10): 3643–52. <a target=xrefwindow id=d15414e2590 href="http://www.ncbi.nlm.nih.gov/pubmed/26813670">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2593 href="http://dx.doi.org/10.1007/s00330-015-4192-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726104848">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726304192"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2606 class=n-a></a>Palmerini E, Jones RL, Marchesi E, <i> et al.</i>: Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. <i>BMC Cancer.</i> 2016; <b>16</b>: 280. <a target=xrefwindow id=d15414e2617 href="http://www.ncbi.nlm.nih.gov/pubmed/27098543">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2620 href="http://dx.doi.org/10.1186/s12885-016-2312-3">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2624 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4839113">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726304192">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725804072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2637 class=n-a></a>Schwartz CL, Wexler LH, Krailo MD, <i> et al.</i>: Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(1): 54–61. <a target=xrefwindow id=d15414e2648 href="http://www.ncbi.nlm.nih.gov/pubmed/26398490">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2651 href="http://dx.doi.org/10.1002/pbc.25753">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2655 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4779061">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725804072">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d15414e2668 class=n-a></a>Gorlick R, Janeway K, Lessnick S, <i> et al.</i>: Children's Oncology Group's 2013 blueprint for research: bone tumors. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(6): 1009–15. <a target=xrefwindow id=d15414e2679 href="http://www.ncbi.nlm.nih.gov/pubmed/23255238">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2682 href="http://dx.doi.org/10.1002/pbc.24429">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2686 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4610028">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d15414e2695 class=n-a></a>Kager L, Whelan J, Dirksen U, <i> et al.</i>: The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. <i>Clin Sarcoma Res.</i> 2016; <b>6</b>: 3. <a target=xrefwindow id=d15414e2706 href="http://www.ncbi.nlm.nih.gov/pubmed/27315524">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2709 href="http://dx.doi.org/10.1186/s13569-016-0043-5">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2713 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4794847">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d15414e2722 class=n-a></a>Bishop MW, Janeway KA, Gorlick R: Future directions in the treatment of osteosarcoma. <i>Curr Opin Pediatr.</i> 2016; <b>28</b>(1): 26–33. <a target=xrefwindow id=d15414e2730 href="http://www.ncbi.nlm.nih.gov/pubmed/26626558">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2733 href="http://dx.doi.org/10.1097/MOP.0000000000000298">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4761449">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d15414e2746 class=n-a></a>Wan J, Zhang X, Liu T, <i> et al.</i>: Strategies and developments of immunotherapies in osteosarcoma. <i>Oncol Lett.</i> 2016; <b>11</b>(1): 511–20. <a target=xrefwindow id=d15414e2757 href="http://www.ncbi.nlm.nih.gov/pubmed/26834853">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2760 href="http://dx.doi.org/10.3892/ol.2015.3962">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2764 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4727173">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725918194"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2773 class=n-a></a>Penel-Page M, Ray-Coquard I, Larcade J, <i> et al.</i>: Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). <i>BMC Cancer.</i> 2015; <b>15</b>: 854. <a target=xrefwindow id=d15414e2784 href="http://www.ncbi.nlm.nih.gov/pubmed/26541413">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2787 href="http://dx.doi.org/10.1186/s12885-015-1894-5">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2791 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4635968">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725918194">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d15414e2804 class=n-a></a>Lagmay JP, Krailo MD, Dang H, <i> et al.</i>: Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. <i>J Clin Oncol.</i> 2016; <b>34</b>(25): 3031–8. <a target=xrefwindow id=d15414e2815 href="http://www.ncbi.nlm.nih.gov/pubmed/27400942">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2818 href="http://dx.doi.org/10.1200/JCO.2015.65.5381">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2822 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5012712">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d15414e2831 class=n-a></a>Benjamin RS: Osteosarcoma: better treatment through better trial design. <i>Lancet Oncol.</i> 2015; <b>16</b>(1): 12–3. <a target=xrefwindow id=d15414e2839 href="http://www.ncbi.nlm.nih.gov/pubmed/25638539">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2842 href="http://dx.doi.org/10.1016/S1470-2045(14)71186-6">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d15414e2851 class=n-a></a>Grignani G, Palmerini E, Dileo P, <i> et al.</i>: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. <i>Ann Oncol.</i> 2012; <b>23</b>(2): 508–16. <a target=xrefwindow id=d15414e2862 href="http://www.ncbi.nlm.nih.gov/pubmed/21527590">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2865 href="http://dx.doi.org/10.1093/annonc/mdr151">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725276475"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2874 class=n-a></a>Grignani G, Palmerini E, Ferraresi V, <i> et al.</i>: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(1): 98–107. <a target=xrefwindow id=d15414e2885 href="http://www.ncbi.nlm.nih.gov/pubmed/25498219">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2888 href="http://dx.doi.org/10.1016/S1470-2045(14)71136-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725276475">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d15414e2902 class=n-a></a>Pappo AS, Vassal G, Crowley JJ, <i> et al.</i>: A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. <i>Cancer.</i> 2014; <b>120</b>(16): 2448–56. <a target=xrefwindow id=d15414e2913 href="http://www.ncbi.nlm.nih.gov/pubmed/24797726">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2916 href="http://dx.doi.org/10.1002/cncr.28728">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d15414e2925 class=n-a></a>Anderson PM, Bielack SS, Gorlick RG, <i> et al.</i>: A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(10): 1761–70. <a target=xrefwindow id=d15414e2936 href="http://www.ncbi.nlm.nih.gov/pubmed/27362300">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2939 href="http://dx.doi.org/10.1002/pbc.26087">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d15414e2948 class=n-a></a>Sampson VB, Gorlick R, Kamara D, <i> et al.</i>: A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. <i>Front Oncol.</i> 2013; <b>3</b>: 132. <a target=xrefwindow id=d15414e2959 href="http://www.ncbi.nlm.nih.gov/pubmed/23755370">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2962 href="http://dx.doi.org/10.3389/fonc.2013.00132">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2966 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3668267">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725275575"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e2975 class=n-a></a>Perry JA, Kiezun A, Tonzi P, <i> et al.</i>: Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(51): E5564–73. <a target=xrefwindow id=d15414e2986 href="http://www.ncbi.nlm.nih.gov/pubmed/25512523">PubMed Abstract </a> | <a target=xrefwindow id=d15414e2989 href="http://dx.doi.org/10.1073/pnas.1419260111">Publisher Full Text </a> | <a target=xrefwindow id=d15414e2993 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4280630">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725275575">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726569550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e3006 class=n-a></a>Bishop MW, Janeway KA: Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma [version 1; referees: 2 approved]. <i>F1000Res.</i> 2016; <b>5</b>: pii: F1000 Faculty Rev-1590. <a target=xrefwindow id=d15414e3014 href="http://www.ncbi.nlm.nih.gov/pubmed/27441088">PubMed Abstract </a> | <a target=xrefwindow id=d15414e3017 href="http://dx.doi.org/10.12688/f1000research.8228.1">Publisher Full Text </a> | <a target=xrefwindow id=d15414e3020 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4937817">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726569550">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d15414e3033 class=n-a></a>Kovac M, Blattmann C, Ribi S, <i> et al.</i>: Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. <i>Nat Commun.</i> 2015; <b>6</b>: 8940. <a target=xrefwindow id=d15414e3044 href="http://www.ncbi.nlm.nih.gov/pubmed/26632267">PubMed Abstract </a> | <a target=xrefwindow id=d15414e3047 href="http://dx.doi.org/10.1038/ncomms9940">Publisher Full Text </a> | <a target=xrefwindow id=d15414e3051 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4686819">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726573351"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15414e3061 class=n-a></a>Engert F, Kovac M, Baumhoer D, <i> et al.</i>: Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. <i>Oncotarget.</i> 2016. <a target=xrefwindow id=d15414e3069 href="http://www.ncbi.nlm.nih.gov/pubmed/27447864">PubMed Abstract </a> | <a target=xrefwindow id=d15414e3072 href="http://dx.doi.org/10.18632/oncotarget.10720">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726573351">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Nov 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2767.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2767.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Klinikum Stuttgart - Olgahospital, Zentrum f&uuml;r Kinder-, Jugend- und Frauenmedizin; P&auml;diatrie 5 (Onkologie, H&auml;matologie, Immunologie), Kriegsbergstrasse 62, Stuttgart Cancer Center, Germany<br/> <sup>2</sup> St. Anna Children's Hospital, Department of Paediatrics, Medical University Vienna and Children's Cancer Research Institute CCRI, Vienna, Austria<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2767/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 25 Nov 2016, 5:2767 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9465.1">https://doi.org/10.12688/f1000research.9465.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Bielack SS <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10194 data-id=9465 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9465.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2767/v1/pdf?article_uuid=dcd86bf4-2e40-4f2f-b441-1443c46f24c0" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9465.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bielack SS, Hecker-Nolting S, Blattmann C and Kager L. Advances in the management of osteosarcoma [version 1; peer review: 2 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2767 (<a href="https://doi.org/10.12688/f1000research.9465.1" target=_blank>https://doi.org/10.12688/f1000research.9465.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9465 id=mobile-track-article-signin-9465 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9465?target=/articles/5-2767.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10194 /> <input name=articleId type=hidden value=9465 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Shreyaskumar Patel</strong>, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Bruno Fuchs</strong>, Laboratory for Orthopaedic Research, Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Switzerland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Nov 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2767.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2767.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18252-17735></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18251-17734></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2767/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>25 Nov 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Shreyaskumar Patel</strong>, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Bruno Fuchs</strong>, Laboratory for Orthopaedic Research, Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Switzerland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2767.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2767/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Advances in the management of osteosarcoma".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2767/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2767/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2767/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bielack SS et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2767/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2767",
            templates : {
                twitter : "Advances in the management of osteosarcoma. Bielack SS et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2767/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Advances in the management of osteosarcoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Advances in the management of osteosarcoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9465/10194")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10194");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "17734": 0,
                           "17735": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "5a379584-72b5-405f-af4f-d912a6d79d10";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2767.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2767.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2767.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2767.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2767.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>